Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Bozko

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Current Medicinal Chemistry|November 6, 2020
Cell-to-Cell Transmission of the Unfolded Protein Response - Is it a Real Phenomenon?Maria Bozko, Przemyslaw Bozko
Current Medicinal Chemistry|July 22, 2017
Editorial: DNA Damage as a Strategy for Anticancer ChemotherapyMaria Bozko, Andrzej Bozko, Tim Scholta, et al.
International Journal of Molecular Sciences|November 27, 2024
High p53 Protein Level Is a Negative Prognostic Marker for Pancreatic AdenocarcinomaSebastian M Klein, Maria Bozko, Astrid Toennießen, et al.
Current Medicinal Chemistry|January 13, 2022
Determination of Both TP53 Mutation Status and the Amount of p53 Protein has Limited Diagnostic Importance for Patients with Ovarian CancerSebastian M Klein, Maria Bozko, Astrid Toennießen, et al.
Current Cancer Drug Targets|April 28, 2016
Deregulation of Apoptosis - Is it Still an Important Issue in Pathogenesis of Chronic Lymphocytic Leukemia?Monika Podhorecka, Arkadiusz Macheta, Maria Bozko, et al.
Current Cancer Drug Targets|February 10, 2021
Cholangiocarcinoma Therapeutics: An UpdateMai Ly Thi Nguyen, Nguyen Linh Toan, Maria Bozko, et al.
The Journal of Biological Chemistry|February 12, 2022
Recharacterization of the mammalian cytosolic type 2 (R)-β-hydroxybutyrate dehydrogenase as 4-oxo-l-proline reductase (EC 1.1.1.104)Sebastian Kwiatkowski, Maria Bozko, Michal Zarod, et al.
Nature|May 13, 2026
SNOR promotes translation restart after dormancyMaciej Gluc, Higor Rosa, Maria Bozko, et al.
Biorxiv : the Preprint Server for Biology|April 3, 2026
A Novel Eukaryotic Ribosome Factor Enables Translation Restart Following Cellular DormancyMaciej Gluc, Higor Rosa, Maria Bozko, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Current Medicinal Chemistry|November 6, 2020
Cell-to-Cell Transmission of the Unfolded Protein Response - Is it a Real Phenomenon?Maria Bozko, Przemyslaw Bozko
Current Medicinal Chemistry|July 22, 2017
Editorial: DNA Damage as a Strategy for Anticancer ChemotherapyMaria Bozko, Andrzej Bozko, Tim Scholta, et al.
International Journal of Molecular Sciences|November 27, 2024
High p53 Protein Level Is a Negative Prognostic Marker for Pancreatic AdenocarcinomaSebastian M Klein, Maria Bozko, Astrid Toennießen, et al.
Current Medicinal Chemistry|January 13, 2022
Determination of Both TP53 Mutation Status and the Amount of p53 Protein has Limited Diagnostic Importance for Patients with Ovarian CancerSebastian M Klein, Maria Bozko, Astrid Toennießen, et al.
Current Cancer Drug Targets|April 28, 2016
Deregulation of Apoptosis - Is it Still an Important Issue in Pathogenesis of Chronic Lymphocytic Leukemia?Monika Podhorecka, Arkadiusz Macheta, Maria Bozko, et al.
Current Cancer Drug Targets|February 10, 2021
Cholangiocarcinoma Therapeutics: An UpdateMai Ly Thi Nguyen, Nguyen Linh Toan, Maria Bozko, et al.
The Journal of Biological Chemistry|February 12, 2022
Recharacterization of the mammalian cytosolic type 2 (R)-β-hydroxybutyrate dehydrogenase as 4-oxo-l-proline reductase (EC 1.1.1.104)Sebastian Kwiatkowski, Maria Bozko, Michal Zarod, et al.
Nature|May 13, 2026
SNOR promotes translation restart after dormancyMaciej Gluc, Higor Rosa, Maria Bozko, et al.
Biorxiv : the Preprint Server for Biology|April 3, 2026
A Novel Eukaryotic Ribosome Factor Enables Translation Restart Following Cellular DormancyMaciej Gluc, Higor Rosa, Maria Bozko, et al.
Pageof 1